Candida lusitaniae fungemia in cancer patients: Risk factors for amphotericin B failure and outcome

Medical Mycology

Volumn 46, Issue 6, 2008, Pages 541-546

  Atkinson, Bradley J ^a   Lewis, Russell E ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Amphotericin B; Cancer; Candida lusitaniae

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR; FLUCONAZOLE; STEROID;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; BLOOD FLOW; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FUNGAL STRAIN; FUNGEMIA; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; FUNGUS MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SOLID TUMOR; STEM CELL TRANSPLANTATION;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CLAVISPORA LUSITANIAE;

EID: 51649122008     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780801968571     Document Type: Review

References (34)

1. Minari, A., Hachem, R. and Raad, I. (2001) Candida lusitaniae: A cause of breakthrough fungemia in cancer patients. Clin Infect Dis, 32, pp. 186-190.
2. Viscoli, C., Girmenia, C. Marinus, A. et al. (1999) Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis, 28, pp. 1071-1079.
3. Nguyen, MH, Morris, AJ Dobson, ME et al. (1996) Candida lusitaniae: An important emerging cause of candidemia. Infect Dis Clin Pract, 5, pp. 273-278.
4. Wingard, R. (1995) Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis, 20, pp. 115-125.
5. Merz, WG. (1984) Candida lusitaniae: Frequency of recovery colonization, infection and amphotericin B resistance. J Clin Microbiol, 20, pp. 1194-1195.
6. Holzschu, DL, Presley, HL, Miranda, M. and Phaff, HJ. (1979) Indentification of Candida lusitaniae as opportunistic yeasts in humans. J Clin Microbiol, 10, pp. 202-205.
7. Sanchez, V., Vasquez, JA Barth-Jones, D. et al. (1992) Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol, 30, pp. 3005-3008.
8. Blinkhorn, RJ, Adelstein, D. and Spagnuolo, PJ. (1989) Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol, 27, pp. 236-240.
9. Kontoyiannis, DP and Lewis, RE. (2002) Antifungal drug resistance of pathogenic fungi. Lancet, 359, pp. 1135-1144.
10. McClenny, NB, Fei, H. Baron, EJ et al. (2002) Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother, 46, pp. 1325-1328.
11. Pietrucha-Dilanchian, P., Lewis, RE, Ahmad, H. and Lechin, AE. (2001) Candida lusitaniae catheter-related sepsis. Ann Pharmacother, 35, pp. 1570-1574.
12. Pappagianis, HD, Collins, MS, Hector, R. and Remington, J. (1979) Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother, 16, pp. 123-126.
13. Yoon, SA, Vasquez, JA Steffan, PE et al. (1999) High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother, 43, pp. 836-845.
14. Rex, JH, Cooper Jr, CR Merz, WG et al. (1995) Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother, 39, pp. 906-909.
15. Guinet, R., Chanas, J. Goullier, A. et al. (1983) Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol, 18, pp. 443-444.
16. Merz, WG and Sandford, GR. (1979) Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol, 9, pp. 677-680.
17. Sanchez, PJ and Cooper, BH. (1987) Candida lusitaniae: Sepsis and meningitis in a neonate. Pediatr Infect Dis J, 6, pp. 758-759.
18. Ascioglu, S., Rex, JH de Pauw, B. et al. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis, 34, pp. 7-14.
19. Bodey, GP, Mardani, M. Hanna, HA et al. (2002) The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med, 1112, pp. 380-385.
20. Klepser, ME, Ernst, EJ, Lewis, RE, Ernst, ME and Pfaller, MA. (1998) Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother, 42, pp. 1207-1212.
21. Komshian, SV, Uwaydah, AK, Sobel, JD and Crane, LR. (1989) Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis, 11, pp. 379-390.
22. Bodey, GP. (1993) Hematogenous and major organ candidiasis. Candidiasis: Pathogenesis, Diagnosis, and Treatment, pp. 279-329. Raven Press, New York
23. Abi-Said, D., Anaissie, E. Uzun, O. et al. (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis, 24, pp. 1122-1128.
24. Fraser, VJ, Jones, M. Dunkel, J. et al. (1992) Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin Infect Dis, 5, pp. 414-421.
25. Anaissie, EJ, Rex, JH, Uzun, O. and Vartivarian, S. (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med, 104, pp. 238-245.
26. Wanger, A., Mills, K., Nelson, PW and Rex, JH. (1995) Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother, 39, pp. 2520-2522.
27. Ernst, EJ, Yodoi, K., Roling, EE and Klepser, ME. (2002) Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother, 46, pp. 578-581.
28. Peyron, F., Favel, A. Michel-Nguyen, AM et al. (2001) Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol, 39, pp. 339-342.
29. Favel, A., Peyron, F. De Meo, M. et al. (1999) Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: Comparison with the Etest and the NCCLS broth macrodilution method. J Antimicrob Chemother, 43, pp. 227-232.
30. Pfaller, MA, Messer, MA and Bolmstrom, A. (1998) Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis, 32, pp. 223-227.
31. Kauffman, CA, Vazquez, JA Sobel, JD et al. (2000) Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis, 30, pp. 14-80.
32. Baker, JG, Nadler, HL, Forgacs, P. and Kurtz, SR. (1984) Candida lusitaniae: A new opportunistic pathogen of the urinary tract. Diagn Microbiol Infect Dis, 2, pp. 145-149.
33. Garcia-Martos, P., Diaz, J., Castano, M., Perez, M. and Marin, P. (1991) Peritonitis caused by Candida lusitaniae in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol, 36, p. 50.
34. Wendt, B., Haglund, L., Razavi, A. and Rath, R. (1998) Candida lusitaniae: An uncommon cause of prosthetic valve endocarditis (letter). Clin Infect Dis, 26, pp. 769-770.